BACKGROUND: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. OBJECTIVES: This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. DESIGN: Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. RESULTS: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). CONCLUSIONS: TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
BACKGROUND: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. OBJECTIVES: This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. DESIGN: Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. RESULTS: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). CONCLUSIONS:TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
Authors: Elisabeth H Thijssen; Inge M W Verberk; Jeroen Vanbrabant; Anne Koelewijn; Hans Heijst; Philip Scheltens; Wiesje van der Flier; Hugo Vanderstichele; Erik Stoops; Charlotte E Teunissen Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Marta Marquié; Mercè Boada; Amanda Cano; Patric Turowski; Miren Ettcheto; Jason Thomas Duskey; Giovanni Tosi; Elena Sánchez-López; Maria Luisa García; Antonio Camins; Eliana B Souto; Agustín Ruiz Journal: J Nanobiotechnology Date: 2021-04-29 Impact factor: 10.435
Authors: James D Doecke; Virginia Pérez-Grijalba; Noelia Fandos; Christopher Fowler; Victor L Villemagne; Colin L Masters; Pedro Pesini; Manuel Sarasa Journal: Neurology Date: 2020-03-16 Impact factor: 9.910
Authors: Shannon L Risacher; Noelia Fandos; Judith Romero; Ian Sherriff; Pedro Pesini; Andrew J Saykin; Liana G Apostolova Journal: Alzheimers Dement (Amst) Date: 2019-07-26
Authors: Kelly Virecoulon Giudici; Philipe de Souto Barreto; Sophie Guyonnet; Yan Li; Randall John Bateman; Bruno Vellas Journal: JAMA Netw Open Date: 2020-12-01